NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 29, 2006--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) announced today that results from human cell line tests have shown that the Company's eukaryotic translation initiation Factor 5A1 ("Factor 5A1" or "eIF-5A1") gene technology reduces the amounts of p24 and IL-8 by approximately 50 percent in HIV-infected cells. The levels of p24, a core protein in HIV cells, and IL-8, a proinflammatory cytokine, rise proportionately with increased HIV replication, making both of them standard indicators of HIV-1 infection.
